Lexaria Bioscience (LEXX) has released an update.
Lexaria Bioscience reports promising interim results in a diabetes animal study, where their DehydraTECH technology, combined with diabetes drugs, has shown significant potential in reducing body weight. Specifically, the DehydraTECH-CBD and DehydraTECH-liraglutide formulations have yielded the most notable weight loss in the study to date.
For further insights into LEXX stock, check out TipRanks’ Stock Analysis page.
